Trial Profile

Evaluation of GSK Biologicals' Boostrix Vaccine When Compared With Decavac in Adults Aged 65 Years or Older.

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 03 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs DTaP vaccine (Primary) ; Diphtheria-tetanus vaccine
Indications Diphtheria; Pertussis; Tetanus
Focus Adverse reactions; Pharmacodynamics; Registrational
Sponsors GlaxoSmithKline

Most Recent Events

30 Dec 2011 Results published in Vaccine.
09 Jul 2011 Based on the results from this trial, the vaccine was approved by the US FDA for use in subjects aged 65 years or older.
16 Jun 2009 Actual end date (1 May 2009) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com